Recently, for epidermal growth factor receptor (EGFR)-mutated NSCLC, the EGFR-TKI, osimertinib, has transitioned to the front-line treatment of choice based on the FLAURA trial48,49 and studies evaluating our radiomic phenotypes in this setting are ongoing. Here, EGFR is linked to non-small cell lung carcinoma.